查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099356

經導管主動脈瓣置換/植入術：市場趨勢、競爭格局和市場預測 - 2034 年

Transcatheter Aortic Valve Replacement/Implantation - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

經導管主動脈瓣置換/移植市場概述

概述：

  • 經導管主動脈瓣置換/植入術（TAVR/TAVI）市場預計在2025年達到85億美元，預計到2034年將達到226億美元。這一成長是由全球主動脈瓣狹窄患病率的上升、微創結構性心臟疾病治療的快速發展以及法規核准的加速推進所推動的，這些加速推進擴大了這些手術的適用患者群體。
  • 全球TAVR/TAVI市場預計在2026年至2034年的預測期內將以11.4%的複合年成長率成長。
  • 就瓣膜框架材質而言，預計到 2025 年，鎳鈦諾材料將引領市場，佔 TAVR/TAVI 市場的 42% 佔有率。
  • 就瓣膜材質而言，到 2025 年，牛源材料將在 TAVR/TAVI 市場佔主導地位，佔市場佔有率的 55%。
  • 以手術方式分類，股動脈入路部分在 TAVR/TAVI 市場中佔主導地位，到 2025 年將佔市場佔有率的 78%。
  • 從適應症來看，主動脈瓣狹窄領域引領了 TAVR/TAVI 市場，到 2025 年將佔 88% 的市場。
  • 按最終用戶分類，預計到 2025 年，醫院領域將引領 TAVR/TAVI 市場，佔 68% 的市場。
  • 到 2025 年，北美將佔全球 TAVR/TAVI 市場收入的 41%，在全球區域市場佔有率中佔最高比例。

經導管主動脈瓣置換/植入術（TAVR/TAVI）是一種微創外科手術，透過導管植入生物瓣膜來取代病變的生物主動脈瓣。它主要用於治療重度主動脈瓣狹窄，並且擴大用於治療主動脈瓣逆流，無需開胸手術。由於瓣膜支架必須安全地擴張並固定在人體解剖結構內，且瓣膜葉片必須經久耐用，並能模擬瓣膜功能且具有良好的血液相容性，因此TAVR裝置融合了先進的冶金技術、生物力學原理和精準的輸送系統。經導管主動脈瓣置換術（TAVR）/經導管主動脈瓣置換術（TAVI）市場按瓣膜支架材料（例如鎳鈦合金、不銹鋼、鈷鉻合金）和瓣葉材料（例如豬源性、牛）進行細分；按手術方式（例如股動脈入路、心尖入路、主動脈入路）進行細分；在全球人口老化、適應症範圍加速擴大（包括無症狀和低風險患者）、再次手術和瓣中瓣手術的應用以及器械持續創新等因素的推動下，TAVR/TAVI 已成為重度主動脈瓣疾病的標準治療方法，並構成了現代結構性心臟介入治療的基礎。

經導管主動脈瓣置換/植入市場的主要市場促進因素

  • 隨著高齡化社會的加劇，全球主動脈瓣狹窄的盛行率不斷上升，符合治療條件的患者群體也不斷擴大。據估計，嚴重主動脈瓣狹窄影響著約 9% 的 65 歲及以上的美國人。
  • 根據 EARLY TAVR 試驗的結果，FDA 批准 Edwards 的 SAPIEN 3 平台於 2025 年用於治療無症狀性的嚴重主動脈瓣狹窄。此類監管擴展正在擴大可治療的患者範圍。
  • 隨著越來越多的醫生和醫院傾向於選擇微創手術而不是開胸主動脈瓣置換術(SAVR)，經導管主動脈瓣置換術 (TAVR) 在所有手術風險類別中的應用正在加速。
  • 包括 FDA 於 2025 年 8 月批准Medtronic Evolut 平台在內的再經導管主動脈瓣置換術 (TAVR) 和瓣中瓣手術適應症的擴大，正在擴大持續和重複手術的基礎。
  • 針對主動脈瓣逆流的新型專用設備，例如 JenaValve 的「Trilogy」系統（首個獲得 FDA 批准用於治療有症狀的嚴重主動脈瓣逆流的經導管瓣膜），為以前未獲得充分治療的患者開闢了治療選擇。
  • 聚合物和乾組織薄膜、人工智慧引導輸送系統以及設備小型化等技術的不斷進步，提高了耐用性，並使治療更年輕、風險更低的患者成為可能。
  • 雅培、美林生命科學和維納斯醫療科技等公司不斷加劇的競爭和地理擴張，正在擴大中低風險患者群體和新興市場獲得治療的機會。

推動經導管主動脈瓣置換/植入市場成長的因素

市場促進因素

由於人口老化，主動脈瓣狹窄的盛行率正在增加。

TAVR/TAVI市場最根本的促進因素是人口老化導致的退化性主動脈瓣疾病（TAVR）在全球日益普遍。據估計，65歲以上的美國人中約有9%患有重度主動脈瓣狹窄，如果不進行治療，約十分之一的症狀性患者可能在症狀出現後的5週內死亡。隨著北美、歐洲和亞太地區預期壽命的延長，患有鈣化性主動脈瓣狹窄的老年患者數量也在穩步成長，而不斷改進的超音波心臟超音波圖篩檢技術正在發現許多以前未被診斷的病例。 TAVR是一種微創手術，是開胸手術的替代方案，恢復速度更快，正逐漸成為這一日益成長的患者群體的標準治療方法，預計到2034年，TAVR手術數量將持續成長。

擴大適應症範圍，包括無症狀和低風險患者。

一系列法規核准正在直接擴大經導管主動脈瓣置換術 (TAVR) 的適用患者群體。 2025 年，美國食品藥物管理局 (FDA) 批准了 Edwards 公司的 SAPIEN 3 平台（包括 SAPIEN 3、SAPIEN 3 Ultra 和 SAPIEN 3 Ultra RESILIA）用於治療無症狀重度主動脈瓣狹窄患者。這是第一個獲準用於治療無症狀疾病的 TAVR 平台，其依據是 EARLY TAVR 試驗的結果，該試驗表明，與指引建議的臨床後續觀察相比，TAVR 具有更優的療效。Medtronic的 Evolut 平台目前已在 120 多個國家獲準用於治療所有手術風險類別（從極高風險到中低風險）的有症狀重度主動脈瓣狹窄患者。隨著合格風險類別和疾病分期的不斷擴大，一些以前未接受治療或接受過外科手術治療的患者將符合 TAVR 的條件，預計在預測期內，TAVR 的需求將進一步成長。

市場限制因素

儘管TAVR/TAVI市場發展勢頭強勁，但仍面臨諸多限制因素。 TAVR器械的高成本以及相關醫院手術基礎設施的不完善，限制了其在價格敏感型市場和新興市場的普及。這是因為與北美和西歐相比，這些市場的經導管手術報銷系統仍不完善。尤其值得注意的是，目前針對年輕、低風險患者（他們正是TAVR的候選者）的長期療效數據仍然相對有限，而外科瓣膜置換術已有數十年的經驗併發症，且關於長期隨訪研究中瓣膜結構劣化的研究仍在進行中。諸如瓣週漏、血管通路損傷以及因傳導障礙需要植入永久性心律調節器等手術併發症，都要求器械和技術不斷改進。許多地區訓練有素的介入性心臟病專家和結構性心臟病團隊的短缺限制了手術量的成長，而二葉式瓣膜和狹窄的瓣葉緣等複雜的解剖結構也持續對現有器械設計構成挑戰。監管和競爭方面的摩擦，包括對併購交易的反壟斷審查（例如聯邦貿易委員會對愛德華茲收購Gennavalve的質疑），都加劇了競爭格局的不確定性。成本、證據、臨床、人才和監管方面的障礙，儘管人口老化、手術偏好和器械創新等強勁的潛在促進因素，卻仍然減緩了成長速度。

區域說明

北美洲

到2025年，北美將佔全球TAVR/TAVI市場收入的41%。美國憑藉其強大的結構性心臟疾病治療基礎設施、豐富的臨床試驗經驗和明確的FDA法規，在該市場佔主導地位。預計到2025年，隨著無症狀性主動脈瓣狹窄、再次TAVR和主動脈瓣逆流等適應症的擴大，美國的TAVR手術量將持續成長。

歐洲

歐洲是一個規模龐大且臨床技術先進的區域市場，這得益於其較早獲得的CE認證、完善的結構性心臟疾病培訓體係以及覆蓋德國、法國、英國、義大利和西班牙的豐富器械產品組合。諸如雅培公司「Navitor」產品於2025年獲得擴大CE認證範圍以及JenaValve公司「Trilogy」產品在歐洲的部署等監管進展，進一步鞏固了該地區作為下一代TAVR器械早期採用市場的地位。

亞太地區

亞太地區是成長最快的地區，這主要得益於中國、日本、印度、韓國和澳洲心血管疾病負擔的日益加重、導管室基礎設施的擴建以及醫療保健投資的成長。 Venus Medtech在中國國內市場的主導地位、Meril Life Sciences在印度具有成本競爭力的「Myval」平台，以及日本人口老化導致的手術量增加，都在加速該地區經導管主動脈瓣置換術（TAVR）的普及和臨床試驗的開展。

世界其他地區

涵蓋拉丁美洲、中東和非洲的「偏遠地區」代表著一個新興的成長前沿。由於心臟醫療基礎設施的不斷改善、主動脈瓣膜疾病診斷數量的增加，以及經導管治療保險報銷和法規核准流程的擴大，這些地區的醫療服務可及性正在逐步提高。巴西的Braile Biomedica等製造商也為此提供支持，他們正在建構區域性的生產和分銷體系。

經導管主動脈瓣置換術/植入市場的最新發展趨勢

2026年5月，雅培在巴黎舉行的2026年歐洲經導管主動脈瓣置換術（EuroPCR 2026）上公佈了Navitor經導管主動脈瓣置換術（TAVI）的真實世界臨床數據，報告顯示該器械在低危險和中危患者中具有良好的安全性和療效。策略意義：這增強了臨床對Navitor瓣環內設計的信心，為其在更廣泛的風險類別中應用奠定了基礎。

2026年1月，雅培公司在「美國心臟病學會雜誌：心血管介入」（JACC: Cardiovascular Interventions）上發表了其用於經導管主動脈瓣置換術（TAVR）的自膨脹式瓣膜「Navitor」在美國的初步真實世界臨床經驗數據。策略意義：這進一步強化了支持「Navitor」差異化設計的臨床證據基礎，使其在競爭激烈的TAVR市場中更具優勢。

常見問題：

問題1：經導管主動脈瓣置換/植入市場的成長率是多少？

預計從 2026 年到 2034 年的預測期內，經導管主動脈瓣置換/植入市場將以 11.4% 的複合年成長率成長。

Q2. 經導管主動脈瓣置換/植入市場的市場規模有多大？

經導管主動脈瓣置換/植入市場預計在 2025 年達到 85 億美元，預計到 2034 年將達到 226 億美元。

Q3.哪些地區正在推動經導管主動脈瓣置換術/植入術（TAVR/TAVI）市場的發展？

北美擁有成熟的結構性心臟疾病治療體系、強大的臨床試驗基礎設施，以及美國食品藥品監督管理局（FDA）明確的監管政策（該政策不斷擴大合格的患者群體），預計主導導管主動脈瓣置換術（TAVR）/經導管主動脈瓣膜置換術（TAVI）市場，到2025年將佔全球銷售額的41%。亞太地區預計將成為預測期內成長最快的地區。

第四季：經導管主動脈瓣置換/植入市場的主要促進因素是什麼？

主要促進因素包括：由於人口老化促使全球主動脈瓣狹窄盛行率上升；適應症擴大，例如 FDA 於 2025 年批准 SAPIEN 3 用於治療無症狀重度主動脈瓣狹窄患病率上升；適應症擴大，例如 FDA 於 2025 年批准 SAPIEN 3 用於治療無症狀重度主動脈瓣狹窄患病率上升；適應症擴大，例如 FDA 於 2025 年批准 SAPIEN 3 用於治療無症狀重度主動脈瓣狹窄；人們越來越傾向於選擇微創手術作為外科主動脈瓣置換置換術的替代方案；再次經導管主動脈瓣置換術 (TAVR) 和手術中以反手術的適應症主動脈瓣擴大症； Trilogy；以及瓣膜設計和輸送系統的持續技術進步。

Q5. 經導管主動脈瓣置換/植入市場的主要參與者有哪些？

主要廠商包括美敦力、愛德華生命科學公司、波士頓科學公司、Meril生命科學公司、雅培、JenaValve Technology公司、Bracco SpA公司、Transcatheter Technologies GmbH公司、Braile Biomedica公司和Venus Medtech公司，以及「競爭格局」部分所述的眾多其他活躍供應商。愛德華生命科學公司和美敦力公司以各自的「SAPIEN」和「Evolut」平台引領市場，而雅培的「Navitor」系統正在縮小差距。

目錄

第1章：經導管主動脈瓣置換/移植市場報告簡介

  • 調查範圍
  • 市場區隔
  • 市場假設

第2章：經導管主動脈瓣置換/移植市場摘要整理

  • 市場概覽

第3章：經導管主動脈瓣置換/移植市場的關鍵因素

  • 經導管主動脈瓣置換/植入市場：市場促進因素
    • 主動脈瓣狹窄盛行率增加
    • 適應性的擴展
    • 傾向微創手術
    • 擴大了經導管主動脈瓣置換術（TAVR）再次手術和瓣中瓣技術的適應症。
  • 經導管主動脈瓣置換/植入市場的市場限制與挑戰。
    • 醫療設備高成本且保險報銷受限
    • 手術的耐久性數據和相關併發症
    • 醫療保健專業人員、解剖學因素和監管複雜性
  • 經導管主動脈瓣置換/植入市場：市場機會
    • 主動脈瓣逆流專用裝置
    • 拓展新興市場和低風險患者群

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：經導管主動脈瓣置換/植入市場的波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章：經導管主動脈瓣置換/移植市場評估

  • 材料
    • 閥框材料
    • 鎳鈦諾
    • 不銹鋼
    • 鈷鉻合金
    • 其他
    • 瓣膜葉片的材料
    • 豬
    • 牛
  • 透過技術
    • 股動脈路徑
    • 尖端入路
    • 主動脈入路
  • 用途別
    • 主動脈瓣狹窄
    • 主動脈瓣逆流
  • 最終用戶
    • 醫院
    • 門診手術中心
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：經導管主動脈瓣置換/移植市場的競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章：經導管主動脈瓣置換/移植市場的新創企業資金籌措和投資趨勢

第10章：經導管主動脈瓣置換/植入市場：公司概況與產品概況

  • Medtronic
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 服務組合
    • 策略舉措/熵
  • Edwards Lifesciences Corporation
  • Boston Scientific Corporation
  • Meril Life Sciences
  • Abbott
  • JenaValve Technology, Inc.
  • Bracco SpA
  • Transcatheter Technologies GmbH
  • Braile Biomedica
  • Venus Medtech

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0209

Transcatheter Aortic Valve Replacement/Implantation Market Summary

Overview:

  • The Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 22.60 billion by 2034. Growth is anchored in the rising global prevalence of aortic stenosis, rapid expansion of minimally invasive structural heart procedures, and accelerating regulatory approvals that broaden the eligible patient population.
  • The global TAVR/TAVI market is growing at a CAGR of 11.4% during the forecast period from 2026 to 2034.
  • By valve frame material, the nitinol segment dominated the TAVR/TAVI market with a 42% share in 2025.
  • By valve leaflet material, the bovine segment dominated the TAVR/TAVI market with a 55% share in 2025.
  • By procedure, the transfemoral approach segment dominated the TAVR/TAVI market with a 78% share in 2025.
  • By application, the aortic stenosis segment dominated the TAVR/TAVI market with an 88% share in 2025.
  • By end user, the hospitals segment dominated the TAVR/TAVI market with a 68% share in 2025.
  • North America dominated the global TAVR/TAVI market revenue with a 41% share in 2025, representing the highest regional market share globally.

Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) is a minimally invasive procedure that delivers a bioprosthetic valve through a catheter to replace a diseased native aortic valve, most commonly to treat severe aortic stenosis and, increasingly, aortic regurgitation, without the need for open-heart surgery. Because the valve frame must safely expand and anchor within the native anatomy while the leaflets replicate durable, blood-compatible valve function, TAVR devices combine advanced metallurgy, biological tissue engineering, and precision delivery systems. The market is organized by material across valve frame material, including nitinol, stainless steel, cobalt chromium, and others, and valve leaflet material, including porcine, bovine, and others; by procedure across transfemoral, transapical, and transaortic approaches; by application across aortic stenosis, aortic regurgitation, and others; and by end user across hospitals, ambulatory surgical centers, and others. Driven by an aging global population, accelerating label expansions into asymptomatic and lower-risk patients, redo and valve-in-valve indications, and continuous device innovation, TAVR/TAVI has become the standard of care for severe aortic valve disease and a cornerstone of modern structural heart intervention.

Transcatheter Aortic Valve Replacement/Implantation Market Key Growth Drivers

  • The rising global prevalence of aortic stenosis in an aging population is expanding the treatable patient pool, with severe aortic stenosis estimated to affect roughly 9% of Americans older than 65.
  • Regulatory label expansions, including the FDA's 2025 approval of Edwards' SAPIEN 3 platform for asymptomatic severe aortic stenosis based on the EARLY TAVR trial, are broadening eligible patient populations.
  • Growing physician and hospital preference for minimally invasive procedures over open surgical aortic valve replacement (SAVR) is accelerating TAVR adoption across all surgical risk categories.
  • Expanding indications for redo TAVR and valve-in-valve procedures, including Medtronic's August 2025 FDA approval of expanded Redo-TAVR for its Evolut platform, are enlarging the durable, recurring procedure base.
  • New dedicated devices for aortic regurgitation, led by JenaValve's Trilogy system, the first FDA-approved transcatheter valve for symptomatic severe aortic regurgitation, are opening previously underserved patient segments.
  • Continuous technological advancement, including polymer and dry-tissue leaflets, AI-guided delivery systems, and device miniaturization, is improving durability and enabling treatment of younger, lower-risk patients.
  • Rising competitive intensity and geographic expansion by companies such as Abbott, Meril Life Sciences, and Venus Medtech are increasing access in intermediate- and low-risk populations and in emerging markets.

Key Companies in Transcatheter Aortic Valve Replacement/Implantation Market

The competitive landscape is led by the following active device manufacturers:

  • Medtronic
  • Edwards Lifesciences Corporation
  • Boston Scientific Corporation
  • Meril Life Sciences
  • Abbott
  • JenaValve Technology, Inc.
  • Bracco SpA
  • Transcatheter Technologies GmbH
  • Braile Biomedica
  • Venus Medtech

Factors Contributing to the Growth of the Transcatheter Aortic Valve Replacement/Implantation Market

Market Drivers

Rising Prevalence of Aortic Stenosis in an Aging Population

The most fundamental driver of the TAVR/TAVI market is the rising global prevalence of degenerative aortic valve disease as populations age. Severe aortic stenosis is estimated to affect approximately 9% of Americans older than 65, and without treatment, roughly one in ten symptomatic patients may die within five weeks of symptom onset. As life expectancy rises across North America, Europe, and Asia-Pacific, the pool of elderly patients with calcific aortic stenosis expands steadily, and improved echocardiographic screening is uncovering substantial underdiagnosed disease burden. Because TAVR offers a minimally invasive alternative to open-heart surgery with faster recovery, it is increasingly the default therapy for this growing population, anchoring durable procedure-volume growth through 2034.

Regulatory Label Expansions into Asymptomatic and Lower-Risk Patients

A wave of regulatory approvals is directly enlarging the treatable population for TAVR. In 2025, the FDA approved Edwards' SAPIEN 3 platform, including SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA, for patients with severe aortic stenosis who are without symptoms, the first such approval in asymptomatic disease, based on the EARLY TAVR trial demonstrating superior outcomes compared to guideline-recommended clinical surveillance. Medtronic's Evolut platform is now approved for symptomatic severe aortic stenosis across all surgical risk categories, from extreme and high risk to intermediate and low risk, in more than 120 countries. Each expansion of eligible risk categories and disease stages converts a segment of previously untreated or surgically managed patients into TAVR candidates, compounding demand across the forecast period.

Market Restraints

Despite strong momentum, the TAVR/TAVI market faces material constraints. The high cost of TAVR devices and associated hospital procedural infrastructure limits adoption in price-sensitive and emerging markets, where reimbursement frameworks for transcatheter therapies remain underdeveloped relative to North America and Western Europe. Long-term durability data, particularly for younger and lower-risk patients now becoming eligible for TAVR, remains comparatively limited next to decades of surgical valve experience, and structural valve deterioration over extended follow-up continues to be studied. Procedural complications, including paravalvular leak, vascular access injury, and the need for permanent pacemaker implantation due to conduction disturbances, require ongoing device and technique refinement. A shortage of trained interventional cardiologists and structural heart teams constrains procedure volume growth in many regions, while complex anatomies, including bicuspid valves and small annuli, continue to challenge existing device designs. Regulatory and competitive frictions, including antitrust scrutiny of consolidation such as the FTC's challenge to Edwards' acquisition of JenaValve, add uncertainty to the competitive landscape. Together, these cost, evidentiary, clinical, workforce, and regulatory barriers temper the pace of growth, even as the underlying drivers of an aging population, procedural preference, and device innovation remain firmly intact.

Transcatheter Aortic Valve Replacement/Implantation Market Segment Analysis

The Transcatheter Aortic Valve Replacement/Implantation by Material (Valve Frame Material [Nitinol, Stainless Steel, Cobalt Chromium, and Others] Valve Leaflet Material [Porcine, Bovine, and Others]), Procedure (Transfemoral, Transapical, Transaortic Approach), Application (Aortic Stenosis, Aortic Regurgitation, Others), End User (Hospitals, Ambulatory Surgical Centers, Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

By Material

Dominant Subsegment: Nitinol. The Nitinol category is expected to dominate the market.

Dominant: Nitinol ~ 42%

The nitinol segment accounted for 42% of the TAVR/TAVI market in 2025. Nitinol is the leading valve frame material because its shape-memory and self-expanding properties allow devices such as Medtronic's Evolut and Venus Medtech's VenusA-Valve to conform precisely to the native annulus without balloon expansion, reducing the risk of annular injury and enabling repositionable, retrievable delivery. Self-expanding nitinol frames are especially favored in patients with irregular or heavily calcified anatomies and support lower-profile delivery systems that ease transfemoral access. While cobalt chromium is growing fastest as balloon-expandable platforms refine frame geometry for precise annular sizing, and stainless steel retains a smaller legacy footprint, the flexibility, recoverability, and broad anatomical applicability of nitinol secure its leadership across the forecast period.

By Procedure

Dominant Subsegment: Transfemoral Approach. The transfemoral approach category is expected to dominate the market.

Dominant: Transfemoral ~ 78%

The transfemoral approach segment accounted for 78% of the TAVR/TAVI market in 2025. Transfemoral access is the leading procedure route because it avoids thoracotomy or sternotomy entirely, is performed under conscious sedation in most centers, and enables shorter hospital stays with faster recovery than any alternative access route. Continuous reductions in delivery-system sheath size have extended transfemoral eligibility to patients with smaller or more diseased peripheral vasculature who previously required alternative access. Transapical and transaortic approaches remain clinically important for patients with prohibitive peripheral vascular disease, small stature, or prior cardiac surgery with dense adhesions, and transapical access is growing quickly as device iterations improve outcomes for these anatomically challenging cases, but the safety, recovery, and workflow advantages of transfemoral access secure its leadership across the forecast period.

Transcatheter Aortic Valve Replacement/Implantation Market Region Analysis

Dominant Region: North America

Dominant: North America ~ 41% (Largest)

North America accounted for 41% of the global TAVR/TAVI market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature structural heart ecosystem, dense hybrid cath-lab infrastructure, deep clinical-trial history led by pivotal trials such as EARLY TAVR, and clear FDA regulatory pathways that have repeatedly expanded eligible patient populations, most recently to asymptomatic severe aortic stenosis in 2025. The United States hosts the largest concentration of experienced structural heart programs and the broadest portfolio of approved devices, including SAPIEN, Evolut, Navitor, and Trilogy. Continued label expansions into redo TAVR, aortic regurgitation, and lower-risk patients, combined with an aging population and strong device reimbursement, anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the TAVR/TAVI market. The region's elevated CAGR is driven by rising cardiovascular disease burden, rapid expansion of cardiac catheterization infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's Venus Medtech has built commanding domestic scale with its VenusA-Valve platform, Japan continues to expand transcatheter procedure volumes under an aging population, India benefits from Meril Life Sciences' indigenously developed, cost-competitive Myval platform, and Australia and South Korea are expanding structural heart training programs. Government healthcare investment, an expanding elderly population, and growing physician training in transcatheter techniques are accelerating adoption, while regional manufacturers scale production and pursue international regulatory approval, positioning Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 41% of the global TAVR/TAVI market revenue in 2025. The United States dominates on the strength of its structural heart infrastructure, deep clinical-trial base, and FDA regulatory clarity, while 2025 label expansions into asymptomatic aortic stenosis, redo TAVR, and aortic regurgitation reinforce continued procedural growth.

Europe

Europe is a large and clinically advanced regional market, supported by early CE Mark approvals, an established structural heart training base, and a broad device portfolio spanning Germany, France, the United Kingdom, Italy, and Spain. Regulatory momentum such as Abbott's 2025 CE Mark expansion for Navitor and JenaValve's European Trilogy activity reinforces the region's role as an early-access market for next-generation TAVR devices.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease burden, expanding cath-lab infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Venus Medtech's domestic leadership in China, Meril Life Sciences' cost-competitive Myval platform in India, and Japan's aging-population-driven procedure growth are accelerating regional TAVR adoption and clinical-trial activity.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac care infrastructure, rising diagnosis of aortic valve disease, and efforts to broaden reimbursement and regulatory pathways for transcatheter therapies are gradually improving access, supported by manufacturers such as Braile Biomedica in Brazil that are building regional manufacturing and distribution capacity.

Transcatheter Aortic Valve Replacement/Implantation Market Competitive Landscape

The TAVR/TAVI market is classified as Highly Concentrated. Two integrated leaders, Edwards Lifesciences and Medtronic, together account for the substantial majority of global TAVR procedure volume through their SAPIEN and Evolut platforms, respectively, anchoring the top tier alongside Abbott's expanding Navitor system. Specialized and fast-scaling providers, including Meril Life Sciences, JenaValve Technology, Boston Scientific, Transcatheter Technologies GmbH, Braile Biomedica, and Venus Medtech, compete through regional manufacturing scale, dedicated aortic regurgitation devices, and cost-competitive platforms, increasing competition in emerging markets and underserved clinical segments.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Highly concentrated, with Edwards Lifesciences and Medtronic leading and a growing field of specialized challengers expanding in adjacent segments.
  • Leading players: Edwards Lifesciences and Medtronic anchor the top tier through their SAPIEN and Evolut platforms, with Abbott's Navitor system closing the gap.
  • Geographic reach: Leaders operate global commercial networks spanning the United States, Europe, and Asia-Pacific; Venus Medtech maintains commanding domestic scale in China while Meril Life Sciences expands across India and emerging markets.
  • Product portfolio strength: Top players offer multiple valve generations spanning balloon-expandable and self-expanding designs, redo TAVR indications, and, increasingly, dedicated aortic regurgitation devices.
  • Clinical evidence: Landmark trials, including EARLY TAVR and VANTAGE, and large post-approval registries are a decisive competitive advantage in expanding label indications.
  • Strategic partnerships and M&A: Active consolidation, including Edwards' 2024 acquisitions of JenaValve and JC Medical to expand its aortic regurgitation pipeline, and Boston Scientific's structural heart investments, continues to reshape the competitive field.
  • Manufacturing capabilities: Precision nitinol and cobalt-chromium frame fabrication, tissue processing and anti-calcification treatment, and low-profile delivery-system engineering are key competitive moats.
  • Innovation focus: Dry-tissue and polymer leaflets, fully retrievable delivery systems, AI-guided implantation, redo TAVR, and dedicated aortic regurgitation devices define the current innovation frontier.

Transcatheter Aortic Valve Replacement/Implantation Market Recent Developmental Activities

In May 2026, Abbott presented real-world Navitor TAVI outcomes data at EuroPCR 2026 in Paris, reporting favorable safety and performance in low- and intermediate-risk patients. Strategic significance: Reinforces clinical confidence in Navitor's intra-annular design ahead of broader risk-category adoption.

In January 2026, Abbott published early U.S. real-world experience data for its intra-annular, self-expanding Navitor valve in JACC: Cardiovascular Interventions. Strategic significance: Strengthens the clinical evidence base supporting Navitor's differentiated design in the competitive TAVR landscape.

Transcatheter Aortic Valve Replacement/Implantation Market Segmentation

Transcatheter Aortic Valve Replacement/Implantation Market by Material

  • Valve Frame Material
  • Nitinol
  • Stainless Steel
  • Cobalt Chromium
  • Others
  • Valve Leaflet Material
  • Porcine
  • Bovine
  • Others

Transcatheter Aortic Valve Replacement/Implantation Market by Procedure

  • Transfemoral Approach
  • Transapical Approach
  • Transaortic Approach

Transcatheter Aortic Valve Replacement/Implantation Market by Application

  • Aortic Stenosis
  • Aortic Regurgitation
  • Others

Transcatheter Aortic Valve Replacement/Implantation Market by End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Transcatheter Aortic Valve Replacement/Implantation Market by Geography

  • North America Transcatheter Aortic Valve Replacement/Implantation Market
  • United States Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Canada Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Mexico Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Europe Transcatheter Aortic Valve Replacement/Implantation Market
  • Germany Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • United Kingdom Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • France Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Italy Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Spain Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Rest of Europe Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Asia-Pacific Transcatheter Aortic Valve Replacement/Implantation Market
  • China Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Japan Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • India Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Australia Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • South Korea Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Transcatheter Aortic Valve Replacement/Implantation Market
  • Middle East Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • Africa Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
  • South America Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)

Key Takeaways from the Transcatheter Aortic Valve Replacement/Implantation Market Report Study

  • Market size analysis for the current transcatheter aortic valve replacement/implantation market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global transcatheter aortic valve replacement/implantation market.
  • Various opportunities available for competitors in the transcatheter aortic valve replacement/implantation market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current transcatheter aortic valve replacement/implantation market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for transcatheter aortic valve replacement/implantation market growth in the future?

Target audience who can benefit from this Transcatheter Aortic Valve Replacement/Implantation market report study

  • Transcatheter aortic valve replacement/implantation product providers
  • Research organizations and consulting companies
  • Transcatheter aortic valve replacement/implantation-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in transcatheter aortic valve replacement/implantation
  • Various end-users who want to know more about the transcatheter aortic valve replacement/implantation market and the latest technological developments in the transcatheter aortic valve replacement/implantation market.

Frequently Asked Questions:

Q1. What is the growth rate of the transcatheter aortic valve replacement/implantation market?

The transcatheter aortic valve replacement/implantation market is projected to expand at a CAGR of 11.4% during the forecast period from 2026-2034.

Q2. What is the market size of the transcatheter aortic valve replacement/implantation market?

The transcatheter aortic valve replacement/implantation market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 22.60 billion by 2034.

Q3. Which region dominates the transcatheter aortic valve replacement/implantation market?

North America dominated the TAVR/TAVI market with a 41% share of global revenue in 2025, supported by a mature structural heart ecosystem, dense clinical-trial infrastructure, and FDA regulatory clarity that has repeatedly expanded eligible patient populations. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the transcatheter aortic valve replacement/implantation market?

The principal drivers are the rising global prevalence of aortic stenosis in an aging population; regulatory label expansions such as the FDA's 2025 approval of SAPIEN 3 for asymptomatic severe aortic stenosis; growing preference for minimally invasive procedures over surgical aortic valve replacement; expanding redo TAVR and valve-in-valve indications; new dedicated devices for aortic regurgitation such as JenaValve's Trilogy; and continuous technological advancement in valve design and delivery systems.

Q5. Who are the major players in the transcatheter aortic valve replacement/implantation market?

The major players include Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, Meril Life Sciences, Abbott, JenaValve Technology, Inc., Bracco SpA, Transcatheter Technologies GmbH, Braile Biomedica, and Venus Medtech, among other active providers profiled in the Competitive Landscape section. Edwards Lifesciences and Medtronic lead through their SAPIEN and Evolut platforms, with Abbott's Navitor system closing the gap.

Table of Contents

1. Transcatheter Aortic Valve Replacement/Implantation Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Transcatheter Aortic Valve Replacement/Implantation Market Executive Summary

  • 2.1 Market at a Glance

3. Transcatheter Aortic Valve Replacement/Implantation Market Key Factors Analysis

  • 3.1 Transcatheter Aortic Valve Replacement/Implantation Market Drivers
    • 3.1.1 Rising Prevalence of Aortic Stenosis
    • 3.1.2 Regulatory Label Expansions
    • 3.1.3 Preference for Minimally Invasive Procedures
    • 3.1.4 Expanding Redo TAVR and Valve-in-Valve Indications
  • 3.2 Transcatheter Aortic Valve Replacement/Implantation Market Restraints and Challenges
    • 3.2.1 High Device Cost and Reimbursement Constraints
    • 3.2.2 Durability Data and Procedural Complications
    • 3.2.3 Workforce, Anatomical, and Regulatory Complexity
  • 3.3 Transcatheter Aortic Valve Replacement/Implantation Market Opportunities
    • 3.3.1 Dedicated Aortic Regurgitation Devices
    • 3.3.2 Emerging-Market and Lower-Risk Patient Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Transcatheter Aortic Valve Replacement/Implantation Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Transcatheter Aortic Valve Replacement/Implantation Market Assessment

  • 7.1 By Material
    • 7.1.1 Valve Frame Material
    • 7.1.1 Nitinol
    • 7.1.2 Stainless Steel
    • 7.1.3 Cobalt Chromium
    • 7.1.4 Others
    • 7.1.2 Valve Leaflet Material
    • 7.2.1 Porcine
    • 7.2.2 Bovine
    • 7.2.3 Others
  • 7.2 By Procedure
    • 7.3.1 Transfemoral Approach
    • 7.3.2 Transapical Approach
    • 7.3.3 Transaortic Approach
  • 7.3 By Application
    • 7.4.1 Aortic Stenosis
    • 7.4.2 Aortic Regurgitation
    • 7.4.3 Others
  • 7.4 By End User
    • 7.4.1 Hospitals
    • 7.4.2 Ambulatory Surgical Centers
    • 7.4.3 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.1.2 Canada Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.1.3 Mexico Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
    • 7.5.2 Europe
      • 7.5.2.1 Germany Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.2.2 United Kingdom Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.2.3 France Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.2.4 Italy Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.2.5 Spain Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.2.6 Rest of Europe Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.3.2 Japan Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.3.3 India Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.3.4 Australia Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.3.5 South Korea Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.3.6 Rest of Asia-Pacific Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
    • 7.5.4 Rest of World
      • 7.5.4.1 Middle East Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.4.2 Africa Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)
      • 7.5.4.3 South America Transcatheter Aortic Valve Replacement/Implantation Market Size in USD million (2023-2034)

8. Transcatheter Aortic Valve Replacement/Implantation Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Transcatheter Aortic Valve Replacement/Implantation Market Startup Funding and Investment Trends

10. Transcatheter Aortic Valve Replacement/Implantation Market Company and Product Profiles

  • 10.1 Medtronic
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Service Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Edwards Lifesciences Corporation
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 Boston Scientific Corporation
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Meril Life Sciences
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Abbott
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 JenaValve Technology, Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 Bracco SpA
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Transcatheter Technologies GmbH
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Braile Biomedica
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10. Venus Medtech
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Transcatheter Aortic Valve Replacement/Implantation Market in Global (2023-2034)
  • Table 2: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Material (2023-2034)
  • Table 3: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Procedure (2023-2034)
  • Table 4: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Application (2023-2034)
  • Table 5: Transcatheter Aortic Valve Replacement/Implantation Market in Global by End-Users (2023-2034)
  • Table 6: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Geography (2023-2034)
  • Table 7: Transcatheter Aortic Valve Replacement/Implantation Market in North America (2023-2034)
  • Table 8: Transcatheter Aortic Valve Replacement/Implantation Market in the United States (2023-2034)
  • Table 9: Transcatheter Aortic Valve Replacement/Implantation Market in Canada (2023-2034)
  • Table 10: Transcatheter Aortic Valve Replacement/Implantation Market in Mexico (2023-2034)
  • Table 11: Transcatheter Aortic Valve Replacement/Implantation Market in Europe (2023-2034)
  • Table 12: Transcatheter Aortic Valve Replacement/Implantation Market in Germany (2023-2034)
  • Table 13: Transcatheter Aortic Valve Replacement/Implantation Market in United Kingdom (2023-2034)
  • Table 14: Transcatheter Aortic Valve Replacement/Implantation Market in France (2023-2034)
  • Table 15: Transcatheter Aortic Valve Replacement/Implantation Market in Italy (2023-2034)
  • Table 16: Transcatheter Aortic Valve Replacement/Implantation Market in Spain (2023-2034)
  • Table 17: Transcatheter Aortic Valve Replacement/Implantation Market in the Rest of Europe (2023-2034)
  • Table 18: Transcatheter Aortic Valve Replacement/Implantation Market in Asia-Pacific (2023-2034)
  • Table 19: Transcatheter Aortic Valve Replacement/Implantation Market in China (2023-2034)
  • Table 20: Transcatheter Aortic Valve Replacement/Implantation Market in Japan (2023-2034)
  • Table 21: Transcatheter Aortic Valve Replacement/Implantation Market in India (2023-2034)
  • Table 22: Transcatheter Aortic Valve Replacement/Implantation Market in Australia (2023-2034)
  • Table 23: Transcatheter Aortic Valve Replacement/Implantation Market in South Korea (2023-2034)
  • Table 24: Transcatheter Aortic Valve Replacement/Implantation Market in Rest of Asia-Pacific (2023-2034)
  • Table 25: Transcatheter Aortic Valve Replacement/Implantation Market in the Rest of the World (2023-2034)
  • Table 26: Transcatheter Aortic Valve Replacement/Implantation Market in the Middle East (2023-2034)
  • Table 27: Transcatheter Aortic Valve Replacement/Implantation Market in Africa (2023-2034)
  • Table 28: Transcatheter Aortic Valve Replacement/Implantation Market in South America (2023-2034)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Transcatheter Aortic Valve Replacement/Implantation Market Drivers
  • Figure 2: Transcatheter Aortic Valve Replacement/Implantation Market Restraints
  • Figure 3: Transcatheter Aortic Valve Replacement/Implantation Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Transcatheter Aortic Valve Replacement/Implantation Market in Global (2023-2034)
  • Figure 9: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Material (2023-2034)
  • Figure 10: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Procedure (2023-2034)
  • Figure 11: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Application (2023-2034)
  • Figure 12: Transcatheter Aortic Valve Replacement/Implantation Market in Global by End-Users (2023-2034)
  • Figure 13: Transcatheter Aortic Valve Replacement/Implantation Market in Global by Geography (2023-2034)
  • Figure 14: Transcatheter Aortic Valve Replacement/Implantation Market in North America (2023-2034)
  • Figure 15: Transcatheter Aortic Valve Replacement/Implantation Market in the United States (2023-2034)
  • Figure 16: Transcatheter Aortic Valve Replacement/Implantation Market in Canada (2023-2034)
  • Figure 17: Transcatheter Aortic Valve Replacement/Implantation Market in Mexico (2023-2034)
  • Figure 18: Transcatheter Aortic Valve Replacement/Implantation Market in Europe (2023-2034)
  • Figure 19: Transcatheter Aortic Valve Replacement/Implantation Market in Germany (2023-2034)
  • Figure 20: Transcatheter Aortic Valve Replacement/Implantation Market in United Kingdom (2023-2034)
  • Figure 21: Transcatheter Aortic Valve Replacement/Implantation Market in France (2023-2034)
  • Figure 22: Transcatheter Aortic Valve Replacement/Implantation Market in Italy (2023-2034)
  • Figure 23: Transcatheter Aortic Valve Replacement/Implantation Market in Spain (2023-2034)
  • Figure 24: Transcatheter Aortic Valve Replacement/Implantation Market in the Rest of Europe (2023-2034)
  • Figure 25: Transcatheter Aortic Valve Replacement/Implantation Market in Asia-Pacific (2023-2034)
  • Figure 26: Transcatheter Aortic Valve Replacement/Implantation Market in China (2023-2034)
  • Figure 27: Transcatheter Aortic Valve Replacement/Implantation Market in Japan (2023-2034)
  • Figure 28: Transcatheter Aortic Valve Replacement/Implantation Market in India (2023-2034)
  • Figure 29: Transcatheter Aortic Valve Replacement/Implantation Market in Australia (2023-2034)
  • Figure 30: Transcatheter Aortic Valve Replacement/Implantation Market in South Korea (2023-2034)
  • Figure 31: Transcatheter Aortic Valve Replacement/Implantation Market in Rest of Asia-Pacific (2023-2034)
  • Figure 32: Transcatheter Aortic Valve Replacement/Implantation Market in the Rest of the World (2023-2034)
  • Figure 33: Transcatheter Aortic Valve Replacement/Implantation Market in the Middle East (2023-2034)
  • Figure 34: Transcatheter Aortic Valve Replacement/Implantation Market in Africa (2023-2034)
  • Figure 35: Transcatheter Aortic Valve Replacement/Implantation Market in South America (2023-2034)
  • Figure 36: Competitive Landscape
  • Figure 37: Startup Funding and Investment Trends